» Articles » PMID: 28291391

Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2017 Mar 15
PMID 28291391
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose We performed a first-in-human clinical trial on ultrasound molecular imaging (USMI) in patients with breast and ovarian lesions using a clinical-grade contrast agent (kinase insert domain receptor [KDR] -targeted contrast microbubble [MB]) that is targeted at the KDR, one of the key regulators of neoangiogenesis in cancer. The aim of this study was to assess whether USMI using MB is safe and allows assessment of KDR expression using immunohistochemistry (IHC) as the gold standard. Methods Twenty-four women (age 48 to 79 years) with focal ovarian lesions and 21 women (age 34 to 66 years) with focal breast lesions were injected intravenously with MB (0.03 to 0.08 mL/kg of body weight), and USMI of the lesions was performed starting 5 minutes after injection up to 29 minutes. Blood pressure, ECG, oxygen levels, heart rate, CBC, and metabolic panel were obtained before and after MB administration. Persistent focal MB binding on USMI was assessed. Patients underwent surgical resection of the target lesions, and tissues were stained for CD31 and KDR by IHC. Results USMI with MB was well tolerated by all patients without safety concerns. Among the 40 patients included in the analysis, KDR expression on IHC matched well with imaging signal on USMI in 93% of breast and 85% of ovarian malignant lesions. Strong KDR-targeted USMI signal was present in 77% of malignant ovarian lesions, with no targeted signal seen in 78% of benign ovarian lesions. Similarly, strong targeted signal was seen in 93% of malignant breast lesions with no targeted signal present in 67% of benign breast lesions. Conclusion USMI with MB is clinically feasible and safe, and KDR-targeted USMI signal matches well with KDR expression on IHC. This study lays the foundation for a new field of clinical USMI in cancer.

Citing Articles

Quantifying Molecular Changes in the Preeclamptic Rat Placenta with Targeted Contrast-Enhanced Ultrasound Imaging.

Shi L, Alencar A, Swan K, Lawrence D, Pridjian G, Bayer C Mol Imaging Biol. 2025; .

PMID: 40014198 DOI: 10.1007/s11307-025-01988-4.


Sequential ultrasound molecular imaging for noninvasive identification and assessment of non-alcoholic steatohepatitis in mouse models.

Sha T, You Y, Miao X, Deng H, Zhang W, Ye H Liver Res. 2025; 7(4):342-351.

PMID: 39958780 PMC: 11791912. DOI: 10.1016/j.livres.2023.11.002.


Molecular Imaging Biomarkers for Early Cancer Detection: A Systematic Review of Emerging Technologies and Clinical Applications.

Malik M, Alqahtani M, Hadadi I, Kanbayti I, Alawaji Z, Aloufi B Diagnostics (Basel). 2024; 14(21).

PMID: 39518426 PMC: 11545511. DOI: 10.3390/diagnostics14212459.


Ultrasound Molecular Imaging Enhances High-Intensity Focused Ultrasound Ablation on Liver Cancer With B7-H3-Targeted Microbubbles.

Xiong X, Zhou H, Xu X, Fu Q, Wan Y, Cao Y Cancer Med. 2024; 13(20):e70341.

PMID: 39431644 PMC: 11492419. DOI: 10.1002/cam4.70341.


A Promising Therapeutic Strategy of Combining Acoustically Stimulated Nanobubbles and Existing Cancer Treatments.

Sharma D, Petchiny T, Czarnota G Cancers (Basel). 2024; 16(18).

PMID: 39335153 PMC: 11431001. DOI: 10.3390/cancers16183181.


References
1.
Wang S, Hossack J, Klibanov A, Mauldin Jr F . Binding dynamics of targeted microbubbles in response to modulated acoustic radiation force. Phys Med Biol. 2013; 59(2):465-84. PMC: 4068277. DOI: 10.1088/0031-9155/59/2/465. View

2.
Willmann J, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M, Lutz A . US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology. 2008; 246(2):508-18. PMC: 4157631. DOI: 10.1148/radiol.2462070536. View

3.
Wang H, Kaneko O, Tian L, Hristov D, Willmann J . Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer. Invest Radiol. 2015; 50(5):322-9. PMC: 4470566. DOI: 10.1097/RLI.0000000000000128. View

4.
Lutz A, Bachawal S, Drescher C, Pysz M, Willmann J, Gambhir S . Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin Cancer Res. 2014; 20(5):1313-22. PMC: 3965293. DOI: 10.1158/1078-0432.CCR-13-1642. View

5.
Abou-Elkacem L, Bachawal S, Willmann J . Ultrasound molecular imaging: Moving toward clinical translation. Eur J Radiol. 2015; 84(9):1685-93. PMC: 4545409. DOI: 10.1016/j.ejrad.2015.03.016. View